Please login to the form below

Not currently logged in
Email:
Password:

hypertension

This page shows the latest hypertension news and features for those working in and with pharma, biotech and healthcare.

AZ divests European rights for cholesterol med Crestor to Grünenthal

AZ divests European rights for cholesterol med Crestor to Grünenthal

In October, AZ also divested the commercial rights to its heart failure and hypertension treatments Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in

Latest news

More from news
Approximately 15 fully matching, plus 267 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    They include: smoking, excessive alcohol consumption, diabetes, depression, hypertension, hearing impairment and mid-life obesity, in addition to a lack of social contact and physical exercise.

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Examples of this approach include developing statins for the treatment of dyslipidemia, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for hypertension, and glucagon-like peptide 1

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... of pulmonary hypertension.

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    First-to-market generics included medicines for opioid overdose, pulmonary arterial hypertension, breast cancer, seizures, depression and various infections.

  • Tools for the digital world Tools for the digital world

    One study showed that patients with uncontrolled hypertension and diabetes achieved significantly greater reduction in blood pressure (BP) and LDL cholesterol, and were more likely to reach their BP goal, than

More from intelligence
Approximately 0 fully matching, plus 37 partially matching documents found.

Latest appointments

  • New faces at Lucid, 90Ten and Page & Page New faces at Lucid, 90Ten and Page & Page

    Downey has 15 years’ medical communications experience, with expertise in several therapy areas, including MS and pulmonary hypertension.

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).

  • New associate director at Packer Forbes New associate director at Packer Forbes

    Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

  • Three directors join UK’s MHRA Three directors join UK’s MHRA

    His research has focused on internal medicine, hypertension and cardiovascular risk management, and he established Edinburgh University's Wellcome Trust cardiovascular research initiative and centre for cardiovascular science.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 10 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....